Compare ARK Space & Defense Innovation ETF (ARKX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs GSK plc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.69, while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while ARK Space & Defense Innovation ETF pays none, and ARK Space & Defense Innovation ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| ARKX | GSK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $61.18 |
52-Week Low | $25.46 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.69, up 0.81% with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on space and defense innovation, with key holdings like SpaceX and Rocket Lab. Recent news highlights strong interest in space economy ETFs as alternatives to direct SpaceX investment, with ARKX noted for outperforming peers in one-year returns despite higher volatility.
The outlook for ARKX is positive due to growing space industry tailwinds, but risks include high expense ratios and volatility. Investment appeal lies in diversified exposure to disruptive tech, though valuation concerns for holdings like SpaceX and competitive ETF options warrant caution for risk-averse investors.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
